ENGOT-cx12/GOG-3037/SNGTV-003
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
GOG-F
ENGOT-cx8/ GOG-3024/GCT1015-05
A Phase 1b/2 open-Label Trial of Tisotumab Vedotin (Humax-TF-ADC) Monotherapy and in combination with other Agents in Subjects with recurrent or Stage IVB Cervical Cancer
Trial Number
NCT03786081Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ANZGOG 0902 / GOG 0274 /RTOG1174
OUTBACK TRIAL - A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone
Trial Number
NCT01414608Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
AGO-OVAR23/DUO-O
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib